07:00 , Oct 31, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Dermatology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Dermatology Wounds Myocardin-related transcription factor A (MKL1; MAL; MRTF-A) Mouse studies suggest MRTF-A activation could help treat dermal...
07:00 , Mar 21, 2013 |  BC Innovations  |  Targets & Mechanisms

Understanding fibrosis

Researchers at The University of Alabama at Birmingham have identified idiopathic pulmonary fibrosis as a repurposing opportunity for fasudil, a Rho kinase inhibitor that Asahi Kasei Pharma Corp. markets as Eril to treat aneurysm. The...
07:00 , Mar 14, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Pulmonary disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Pulmonary disease Pulmonary fibrosis Rho kinase; myocardin-related transcription factor A (MKL1; MAL; MRTF-1) Human tissue and mouse studies...